Table 2.
Change in the ERP familiarity response (familiar-unfamiliar) from baseline to the 9-month follow-up as a function of treatment.
| Placebo n = 9 | Choline n = 10 | ||
|---|---|---|---|
| M (SD) | M (SD) | t test | |
| Nc Adaptive Mean Amplitude (μV) | |||
| Prefrontal | −4.02 (9.07) | 3.36 (10.56) | p = 0.123 |
| Right frontal | −0.47 (3.25) | −0.39 (5.97) | p = 0.972 |
| Left frontal | −0.01 (7.06) | 1.14 (5.43) | p = 0.695 |
| Central | −3.17 (5.36) | 2.06 (6.12) | p = 0.065 |
| Nc Latency Peak Amplitude (ms) | |||
| Prefrontal | 53.06 (94.89) | −44.08 (113.51) | p = 0.061 |
| Right frontal | 8.46 (64.62) | 3.18 (117.02) | p = 0.906 |
| Left frontal | 44.04 (79.61) | −29.45 (93.73) | p = 0.085 |
| Central | 34.64 (85.44) | −41.42 (98.68) | p = 0.092 |
| PSW (area under the curve) | |||
| Prefrontal | −4.19 (8.77) | 1.89 (13.89) | p = 0.276 |
| Right frontal | 0.93 (3.03) | 0.42 (5.68) | p = 0.812 |
| Left frontal | 0.02 (6.12) | 1.31 (4.58) | p = 0.607 |
| Central | −2.36 (5.35) | 2.60 (8.01) | p = 0.135 |
These analyses include participants who had usable ERP data at both baseline and the 9-month follow-up (n = 19). Of the 24 participants with usable ERP data at follow-up, five had missing ERP data at baseline due to too few artifact-free trials.